You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 797 Real-world treatment duration of atezolizumab+carboplatin+etoposide among older patients with extensive-stage small cell lung cancer (ES-SCLC) and the impact of performance status and brain metastases

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
797 Real-world treatment duration of atezolizumab+carboplatin+etoposide among older patients with extensive-stage small cell lung cancer (ES-SCLC) and the impact of performance status and brain metastases

 

Online download statistics by month:

Online download statistics by month: November 2022 to November 2024

AbstractFullPdf
Nov 2022184016
Dec 20226404
Jan 20236801
Feb 20238209
Mar 20236802
Apr 20235005
May 20236607
Jun 202372013
Jul 202370010
Aug 20235002
Sep 20234007
Oct 20233804
Nov 20236208
Dec 20237008
Jan 20243002
Feb 20242203
Mar 202444022
Apr 202436016
May 20244407
Jun 20242806
Jul 20241802
Aug 20242206
Sep 202450013
Oct 202456011
Nov 20245609
Total13900193